A recall of its baby powder sparked worries about the healthcare giant's asbestos-related legal battles.
News & Analysis: Johnson & Johnson
Atlassian's results aren't good enough, and Johnson & Johnson takes a hit to its reputation.
JNJ earnings call for the period ending September 30, 2019.
Does this mean anything for the pharmaceutical giant's long-term outlook?
These companies could be long-term winners for your income-focused portfolio.
Which stock wins in a battle between these two big drugmakers?
At least one analyst believes Johnson & Johnson's legal liabilities are vastly overstated.
Bad news is priced in, leaving behind value and growth.
You might be surprised how many of these companies' products are found in and around your home.
A near-quadrupling in the Dow Jones Industrial Average is a very real possibility by 2035.